Abstract
Background
Methods
Results
Conclusions
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineReferences
- Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patients.Mayo Clin Proc. 2019; 94: 1670-1680
- Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.N Engl J Med. 2019; 380: 11-22
US Food and Drug Administration. FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. Available at:https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups. Accessed January 16, 2020.
- Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association.Circulation. 2019; 140: e673-e691
Standards of medical care in diabetes-2020; 10. Cardiovascular disease and risk management: diabetes care. 2020;43:S111-134.
- National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.J Clin Lipidol. 2019; 13: 860-872
Ollendorf D, McQueen R, Campbell J, et al. Final Evidence Report: Additive Therapies for Cardiovascular Disease: Effectiveness and Value. Available at:http://icer-review.org/material/cvd-final-evidence-report/. Accesed May 19, 2020.
- The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy.J Clin Lipidol. 2019; 13: e20-e22
FDA Endocrinologic and Metabolic Drugs Advisory Subcommittee. Amarin Pharmaceuticals Ireland Limited Advisory Committee Briefing Document on Vascepa® (icosapent ethyl; AMR101). Available at: https://www.fda.gov/media/132479/download. Accessed August 5, 2020.
- Number needed to treat is incorrect without proper time-related considerations.J Clin Epidemiol. 2012; 65: 42-46
- Absolute risks rather than incidence rates should be used to estimate the number needed to treat from time-to-event data.J Clin Epidemiol. 2013; 66: 1038-1044
Centers for Medicare & Medicaid Services. National average drug acquisition cost. Available at:https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-National-Average-Drug-Acquisition-Cost-/a4y5-998d/data. Accessed August 5, 2020.
- A transparent and consistent approach to assess US outpatient drug costs for use in cost-effectiveness analyses.Value Heal. 2018; 21: 677-684
- Eligibility and cost for icosapent ethyl based on the reduce-it trial: Insight from the veterans affairs healthcare system.Circulation. 2019; 139: 1341-1343
- The ICER value framework: integrating cost effectiveness and affordability in the assessment of health care value.Value Heal. 2018; 21: 258-265
- A feasible, simple, cost-saving program to end cardiovascular disease in the United States.Am J Med. 2019; 132: 1365-1367
- The cost-effectiveness of omega-3 polyunsaturated fatty acids – the Australian healthcare perspective.Eur J Intern Med. 2019; 67: 70-76
Ademi Z, Ofori-Asenso R, Zomer E, Owen A, Liew D. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction [e-pub ahead of print]. Eur J Prev Cardiol. Accessed month day, year. doi: 10.1177/2047487319896648. Accesed May 19, 2020
- Confidence intervals for the number needed to treat.BMJ. 1998; 317: 1309-1312
- Effects of icosapent ethyl on total ischemic events: from REDUCE-IT.J Am Coll Cardiol. 2019; 73: 2791-2802
Article info
Publication history
Footnotes
Funding: None.
Conflicts of Interest: JA has received nonfinancial support from Janssen Pharmaceuticals and speaker and consulting honorarium from Pfizer and NovoNordisk. RA, EA, AH report none.
Authorship: All authors had access to the data and a role in writing this manuscript.
